Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation.

Jiexin Zhang, Yunya Zhang, Yaru Zhao, Huiyue Shen, Yan Zhao, Hongbo Teng

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Phillygenin suppresses hepatocellular carcinoma progression by modulating the TNF signaling pathway and TCA cycle metabolism.Frontiers in pharmacology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiexin ZhangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.

Yunya ZhangCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.

Yaru ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.

Huiyue ShenCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.

Yan ZhaoCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.ORCID 0000-0003-0704-7410

Hongbo TengCollege of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.

Funding

Ningxia Natural Science Foundation Project No. 2025AAC030371

6 · The paper itself

Abstract

Lung cancer ranks among the most commonly diagnosed malignancies worldwide, with dismal prognosis largely due to its intrinsic drug resistance and high recurrence rate. Herein, we synthesized 30 glycyrrhetinic acid derivatives and evaluated their anti-lung cancer potential both in vitro and in vivo. The biological effects of compound

Indexed as

Antineoplastic AgentsApoptosisGlycyrrhetinic AcidLung NeoplasmsSignal TransductionTumor Necrosis Factor-alphaA549 CellsAnimalsCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudeMolecular Docking SimulationXenograft Model Antitumor AssaysAntineoplastic AgentsGlycyrrhetinic AcidTumor Necrosis Factor-alphaapoptosisglycyrrhetinic acid derivativeslung cancerstructural modificationTNF

Identifiers

PMID41751830

DOI10.3390/ijms27041693

PMCPMC12940428

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.